AGITG Trial News

The AGITG currently has six studies open to recruitment and ten studies in follow up. Please find following, a table indicating the trials which are still recruiting, and where the recruited patients numbers measure up against the trial target. Recruited Target ACTICCA-1- gallbladder carcinoma 0 50 ALT-GIST- GI Stromal Tumour 18 240 … Read More

July 25, 2016

2016 Pancreas Cancer Research Workshop

Call for Submissions: AGITG – APC Pancreas Cancer Research Workshop The AGITG and the Australasian Pancreatic Club (APC) are again hosting a Pancreas Cancer Research Workshop to be held on 13 September in conjunction with the AGITG Annual Scientific Meeting.  Now is the time to develop a concept to present. When: … Read More

July 19, 2016

TACTIC Study published

The AGITG TACTIC study, a Phase II trial of gemcitabine, cisplatin and panitumumab in biliary tract cancer was recently published in the Cancer Chemotherapy and Pharmacology Journal. The aim of the study was to determine the activity and safety gemcitabine, cisplatin and panitumumab in patients with K-ras wild-type locally advanced, … Read More

July 4, 2016

INTEGRATE results published in JCO

The manuscript “Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): a Multinational Placebo- Controlled Phase II Trial” was recently published in the Journal of Clinical Oncology. To read the full article click here. INTEGRATE was a randomised phase II double-blind placebo-controlled study of regorafenib in refractory Advanced Oesophago-Gastric Cancer. … Read More

June 23, 2016

Pancreatic cancer surgical guidelines published

New surgery guidelines have been developed by a team of leading Australian pancreatic cancer experts, who hope this detail will be a major step forward to improved survival rates over the next five years. A report, published today in the Medical Journal of Australia, notes pancreatic cancer is fast becoming … Read More

June 20, 2016

GAP Poster presented at ASCO

Dr Howard Chan (right front) with Mr Luke Garrick and Ms Mary Rophael from STA at the recent ASCO meeting in Chicago. Over 2,500 Australians are diagnosed with pancreatic cancer each year; even for patients that get curative treatment their 5 year survival is still low at 20%. Thus research … Read More

June 9, 2016

Excellence & Innovation in GI cancer research since 1991

For 25 years, the Australasian Gastro-Intestinal Trials Group has been conducting and promoting clinical and related biological research in Australasia and internationally, addressing key unanswered questions to achieve better health outcomes for patients with GI cancer. AGITG opens first clinical trials to patient participation under the auspices of the NHMRC … Read More

June 9, 2016

AGITG 2016 Annual General Meeting Report

The 2016 Annual General Meeting was held on Friday 13th May at Rydges Sydney International Airport Hotel.  The Notice of Meeting was circulated to members electronically on Tuesday 15th April. Financial Report Members voted by show of hands and by proxy to accept the 2015 Financial Report. Election of Board Members In … Read More

June 9, 2016

ASCO update on GI Cancer

From June 3 – 7 more than 30,000 cancer specialists — including doctors, researchers, and patient advocates — gathered in Chicago to talk about the latest research in state-of-the-art treatments, new therapies, and patient care. The theme for this year’s meeting was Collective Wisdom: The Future of Patient-Centered Care and … Read More

June 6, 2016

Best of New Concepts Award

Professor Rob Ramsay receiving the award in 2015 with Luke Garrick and Mary Rophael from Specialised Therapeutics Australia The New Concepts Symposium sponsored by Specialised Therapeutics Australia is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to … Read More

June 6, 2016